Denying may yet make sense (letter) by Buskens, E.
  
 University of Groningen




IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Buskens, E. (2008). Denying may yet make sense (letter). Archives of Surgery, 143(2), 209-209.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
CORRESPONDENCE
Denying May Yet Make Sense
T imaran and others
1 report on what essentially ap-
pears tobe a registry-basedobservational studyand
go at length to explain why their results may be
used to refute the results of the EVAR (endovascular aor-
tic aneurysm repair) 2 trial.2 They recognize the fact that
by definition their design is inferior but still claim that no
patients should be denied “rescue” by a vascular surgeon.
Interestingly, framing the message as denying care in-
stead of what more appropriately may be called offering
optimal medical care already sets the scene.
However, the pivotal problem that can never be re-
solved, even if the study represented the experience of the
entire world, is what would have happened had these pa-
tients not been offered EVAR. The latter notion seems be-
yond the authors’ conception. The fact is that the authors
simplydonotprovide a satisfactory explanation for thehuge
difference in complication rates between their series and
the EVAR 2 trial. Thismakes interpretation extremely dif-
ficult, and therefore this study cannot provide a proper ba-
sis for a considered health care policy decision.
Finally, and not least important, is the fact that the
authors completely neglect the issue of competing mor-
bidity andmortality in this high-risk population. It would
appear that if the EVAR1 andDREAM trials showed equal
overall survival 1 year after randomization simply be-
cause of increased cardiovascular mortality in EVAR sur-
vivors, the margin for a relevant survival benefit would
be extremely small if existent at all.3,4 Have the authors
even considered the possibility that not denial of care but
optimal medical care may be the best option for this frail
population, also from a health economic perspective?
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study, it is likely the largest cohort of its kind and represents
the early outcomes of the vast majority of EVARs performed
in the United States over the last 5 years.1 Most other studies
comparesmallerpopulations,arerestricted tomajoracademic
centers,andhavehighlyselectedpatientsandoperators.2-5Our
findings, however, confirm those of other large observational
studies, which have clearly established that the high 30-day
and in-hospital mortality reported in the EVAR trial 2 is not
seen in the United States, even in the highest-risk patients or
those unfit for open repair.2,3 Although no randomized trial,
except for EVAR 2, has assessed the perioperative outcomes
ofEVARamong thehighest-risk patients, the immediate need
of data that could justify its use warranted additional inves-
tigation in theUnitedStates todefinehealthcarepolicy. In this
regard,we do agreewithDrBuskens that the proper basis for
health carepolicydefinitionneeds to include the results of sev-
eral studies that reflect the outcomes and current practices in
a particular country. Our study, in conjunction with others,
has clearly proven that the perioperative mortality of EVAR
in the United States is low, even in the highest-risk patients.
Our conclusion, ie, that EVAR should not be denied to high-
risk patients with abdominal aortic aneurysm in the United
Stateson thebasisof the level1evidence fromtheBritishstudy,
is therefore supported by others.2,3
DrBuskens claims thatwehaveneglected the issueofmor-
bidityandmortalityofthehighest-riskpatientsundergoingEVAR
and have not considered the importance of optimal medical
therapy to improve outcomes. Although our study focused on
perioperative in-hospitalmortality, other observational stud-
ieshaveconfirmedthatEVARcanresult in improved long-term
survival inall risk categories, includingpatientsunfit foropen
repair.2,3Obviously, improvedperioperativeoutcomesandpa-
tient survival do not result only from an optimal surgical or
interventionalprocedure, butalso fromoffering thebestmedi-
calmanagement. In this regard,wedobelieve that refinements
andeffectivenessinassessingandimproving“fitness”withtreat-
ment of comorbidities, provider experience, and lack of treat-
mentdelaysmayaccountfortheimprovedoutcomesintheUnited
States as compared with those reported in the EVAR 2 trial.
As vascular specialists,wedonot “neglect” bestmedicalman-
agement.Quite the opposite:we incorporate it in themanage-
ment of all patients undergoing vascular procedures.
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